Eric Weisblum Biography and Net Worth

CEO of Silo Pharma

Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both inlicensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum is involved in his community and can often be found on the soccer field with his family of four. He holds a B.A. from the University of Hartford’s Barney School of Business.

What is Eric Weisblum's net worth?: The estimated net worth of Eric Weisblum is at least $21.10 thousand as of December 15th, 2025. Weisblum owns 14,462 shares of Silo Pharma stock worth more than $21,100 as of October 9th. This net worth estimate does not reflect any other investments that Weisblum may own. Learn More about Eric Weisblum's net worth.
How do I contact Eric Weisblum?: The corporate mailing address for Weisblum and other Silo Pharma executives is 677 N. Washington Blvd, Sarasota, FL, 34236. Silo Pharma can also be reached via phone at (718) 400-9031 and via email at [email protected]. Learn More on Eric Weisblum's contact information.
Has Eric Weisblum been buying or selling shares of Silo Pharma?: Eric Weisblum has not been actively trading shares of Silo Pharma during the past quarter. Most recently, on Monday, December 15th, Eric Weisblum bought 333 shares of Silo Pharma stock. The stock was acquired at an average cost of $6.15 per share, with a total value of $2,047.95. Following the completion of the transaction, the chief executive officer now directly owns 14,462 shares of the company's stock, valued at $88,941.30. Learn More on Eric Weisblum's trading history.
Are insiders buying or selling shares of Silo Pharma?: During the last twelve months, Silo Pharma insiders bought shares 2 times. They purchased a total of 399 shares worth more than $2,414.25. The most recent insider tranaction occured on December, 15th when CEO Eric Weisblum bought 333 shares worth more than $2,047.95. Insiders at Silo Pharma own 3.6% of the company. Learn More about insider trades at Silo Pharma.
Information on this page was last updated on 12/15/2025.

Eric Weisblum Insider Trading History at Silo Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2025	Buy	333	$6.15	$2,047.95	14,462
11/20/2025	Buy	66	$5.55	$366.30	14,062
5/27/2025	Buy	666	$6.45	$4,295.70	13,195
12/13/2024	Buy	166	$12.60	$2,091.60	12,528
11/22/2024	Buy	166	$13.50	$2,241.00	12,362
11/20/2024	Buy	166	$14.25	$2,365.50	12,195
6/11/2024	Buy	37	$16.20	$599.40	11,732
4/4/2024	Buy	40	$29.40	$1,176.00	11,668
4/1/2024	Buy	73	$28.65	$2,091.45	11,628
3/28/2024	Buy	227	$29.10	$6,605.70	11,555
12/19/2023	Buy	33	$24.45	$806.85	11,314
12/14/2023	Buy	13	$22.50	$292.50	11,221
12/7/2023	Buy	21	$20.40	$428.40	11,208
12/5/2023	Buy	40	$20.85	$834.00	11,181
11/30/2023	Buy	66	$22.95	$1,514.70	11,141
11/27/2023	Buy	16	$26.70	$427.20	11,008
11/22/2023	Buy	26	$25.20	$655.20	10,991
11/16/2023	Buy	73	$19.95	$1,456.35	10,554
5/17/2023	Buy	166	$30.90	$5,129.40	10,481
12/19/2022	Buy	13	$40.20	$522.60	10,314

Eric Weisblum Buying and Selling Activity at Silo Pharma

Silo Pharma Company Overview

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Today's Range

Now: $1.43

$1.40

$1.44

50 Day Range

MA: $2.50

$1.44

$4.67

2 Week Range

Now: $1.43

$1.30

$10.43

Volume

5,507 shs

Average Volume

184,725 shs

Market Capitalization

$2.27 million

P/E Ratio

N/A

Dividend Yield